- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02455414
Tracking Neurodegeneration in Early Wolfram Syndrome (TRACK)
Study Overview
Status
Detailed Description
Specific Aims: Wolfram syndrome (WFS) is a rare (1 in ~770,000) autosomal recessive genetic disease characterized by early childhood onset insulin dependent diabetes, optic nerve atrophy, vision and hearing loss, diabetes insipidus and neurodegeneration, resulting in death in middle adulthood, typically due to brainstem atrophy-induced respiratory failure 3. There are no interventions to slow or stop this devastating deterioration. However, much is known about the mechanisms underlying these effects. The causative gene (WFS1) was identified by the investigators group in 19984, and a number of loss-of-function mutations have been described 4-6. Cell 7 and animal models 8 have determined that WFS1 encodes an endoplasmic reticulum (ER) membrane-embedded protein called wolframin 9, and that mutant forms of the WSF1 protein lead to disturbances of ER calcium homeostasis, driving ER stress-mediated apoptosis 10-12. This process kills insulin producing pancreatic β-cells, leading to diabetes. WFS1 is also expressed throughout the brain, and cell death via ER stress is thought to underlie neurodegeneration in WFS 6,13, as well as being implicated in more common neurodegenerative and endocrine (Type 1 and Type 2 diabetes) diseases 14. Work in animal models of WFS is progressing rapidly towards the identification of viable interventions for the ER stress related cell death12. Some neurological features of the disease may be feasible to target and monitor in clinical trials, due to the fact that diabetes is already present when a patient is diagnosed with WFS. Unfortunately, there is limited information on the pattern of brain changes associated with WFS. Although clinical retrospective data suggest that neurological features occur late (15-30 yrs of age; Fig 10) in the disease process15,16, direct measurements (Preliminary Data) suggest that certain neurological abnormalities are present at the earliest time point assessed, suggesting altered neurodevelopment, whereas others follow a more neurodegenerative pattern. These distinctions are fundamentally new insights into this disease and may shape treatment, biomarker selection and the investigators understanding of the impact of ER stress on the developing brain. A better understanding of the neurodegenerative and neurodevelopmental changes in early WFS is a necessary first step towards being ready for future clinical trials. Thus, the primary goal of this proposal is to determine the pattern of brain alterations in WFS over time. Only by understanding the natural history of brain functional and structural changes in WFS will the investigator be prepared to evaluate any benefits of novel treatments. The investigator will perform cross-sectional and longitudinal assessments of youth with WFS, targeting sensitive neural systems with quantified neuroimaging and relevant behavioral measures. In addition, the investigator will validate a new WFS severity rating scale (WFS Unified Rating Scale or WURS), which will have utility in future multi-site or treatment studies. Preliminary data support the feasibility of this approach and its potential to generate important new information about neurologic patterns in WFS. A better understanding of the trajectory of ER stress-mediated brain changes in WFS may be relevant to other more common diseases. Specific aims follow:
- To determine the pattern of neurologic impairment in WFS and its association with disease severity in a cross-sectional sample. The investigator hypothesizes that specific brain measures will be altered earlier and will associate more closely with overall disease severity than others in WFS. The investigator proposes that regional white matter microstructural integrity in the cerebellum, optic nerve area, brain stem volume, balance and possibly anxiety will distinguish individuals with early WFS from controls and will correlate with severity on a standardized rating scale. To test this hypothesis, the investigator will perform quantified neuroimaging, cognitive, motor, psychiatric, visual and auditory evaluations on individuals with WFS, preferentially recruiting those earlier in the disease process, (n=30; age 5 and older, within 10 years of diabetes onset) and on matched healthy controls (n=30) and controls with Type 1 Diabetes Mellitus (T1DM; n=30).
- To determine the longitudinal pattern of neurologic deterioration in WFS. The investigator hypothesize that measures specified in Aim 1 will show detectable change, and that the most sensitive measures will show change in the early Wolfram patients compared to control groups. To test this hypothesis, WFS, T1DM and control participants will be re-assessed annually for 3 years. Variables of interest identified in cross-sectional analyses will be targeted and compared between groups and correlated with change in disease severity as measured with the investigators standardized rating scale.
- To explore brain structure-function relationships within WFS. To determine if neuroimaging measures identified in Aims 1 and 2 have functional correlates, the investigator will explore how differences (cross-sectional data) or change (longitudinal data) in neuroimaging variables correlate with differences or change in selected functional measures. Such data would help build hypotheses about the neural underpinnings of functional changes in WFS. For example, the investigator speculates that the integrity of the brainstem and cerebellum will be related to gait and balance and that optic nerve area will be related to visual acuity.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Wolfram Syndrome Group (WFS):
Inclusion Criteria:
- Participant has confirmation of a WFS1 mutation OR
- Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old
Exclusion Criteria:
- Participant is unaware of their diagnosis.
- Inability of patient or guardian to understand informed consent.
- Advanced disease that makes traveling too problematic and/or uncomfortable for the patient and/or guardian, such as use of ventilator or inability to walk.
T1DM Group:
Inclusion criteria:
- Age within the 0-28 yrs age range of WS participant
- Dx of T1 diabetes mellitus
Exclusion criteria:
- Participant is unaware of their diagnosis.
- Inability of patient or guardian to understand informed consent.
- Diagnosis of any major neurological or medical condition.
- Chronic disease other than T1DM, well-controlled asthma, or Hashimoto's thyroiditis.
- Other current serious medical illness
- Co-morbid psychiatric illness: such as mania, mental retardation, or psychoactive drug dependence.
- Co-morbid neurological illness: stroke, seizure, major loss of consciousness, other brain trauma/surgery, or head injuries (i.e. near drowning), encephalitis, or hydrocephalus, blindness, deafness.
- Pre-maturity at birth >4 wks early (<36 wk term) w/ sequelae (e.g. on respirator at NICU)
- Contraindication to MRI scan (e.g. claustrophobia, metal implants, foreign bodies)
- Orthodontic braces. Full and top braces will exclude.
Healthy Control (HC) Group:
Inclusion criteria:
• Age within the 0-28 yrs age range of WFFS participants
Exclusion criteria:
- Inability of patient or guardian to understand informed consent.
- Dx of T1 diabetes mellitus
- Diagnosis of any major neurological or medical condition.
- Chronic disease other than well-controlled asthma, or Hashimoto's thyroiditis.
- Other current serious medical illness
- Co-morbid psychiatric illness: such as mania, mental retardation, or psychoactive drug dependence.
- Co-morbid neurological illness: stroke, seizure, major loss of consciousness, other brain trauma/surgery, or head injuries (i.e. near drowning), encephalitis, or hydrocephalus, blindness, deafness
- Pre-maturity at birth >4 wks early (<36 wk term) w/ sequelae (e.g. on respirator at NICU)
- Contraindication to MRI scan (e.g. claustrophobia, metal implants, foreign bodies)
- Orthodontic braces. Full and top braces will exclude. Bottom braces are ok (but the scan might not work out). Retainers are ok.
Proxy Group: Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the four groups.
Inclusion criteria:
• Biological or non-biological parent/caregiver (proxy) of a participant.
Exclusion criteria:
• Proxy is unaware of the participant's diagnosis (as it applies).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Proxy Group
Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the groups.
|
Wolfram Syndrome Group
|
WFS Pre-symptomatic Sibling Group
|
WFS Control Sibling Group
|
T1DM Group
|
Healthy Control (HC) Group
• Age within the 0-28 yrs age range of WFS participants
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in regional brain volume
Time Frame: annually for 5 years
|
MRI measures of regional brain volumes over time
|
annually for 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in disease severity score
Time Frame: annually for 5 years
|
WURS physical severity score over time
|
annually for 5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Tamara Hershey, PhD, Washington University Medical School
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Nervous System Diseases
- Kidney Diseases
- Urologic Diseases
- Eye Diseases
- Neurologic Manifestations
- Endocrine System Diseases
- Disease
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Otorhinolaryngologic Diseases
- Neurodegenerative Diseases
- Ear Diseases
- Eye Diseases, Hereditary
- Heredodegenerative Disorders, Nervous System
- Optic Nerve Diseases
- Cranial Nerve Diseases
- Sensation Disorders
- Optic Atrophies, Hereditary
- Optic Atrophy
- Pituitary Diseases
- Abnormalities, Multiple
- Hearing Disorders
- Vision Disorders
- Deaf-Blind Disorders
- Blindness
- Hearing Loss
- Deafness
- Diabetes Mellitus, Type 1
- Diabetes Mellitus
- Syndrome
- Nerve Degeneration
- Diabetes Insipidus
- Wolfram Syndrome
Other Study ID Numbers
- 201301004
- R01HD070855-02 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States